Literature DB >> 17626401

Variation in the approach to VATS lobectomy: effect on the evaluation of surgical morbidity following VATS lobectomy for the treatment of stage I non-small cell lung cancer.

Norihisa Shigemura1, Anthony P C Yim.   

Abstract

Recent advances in imaging, chemical pathology, and target therapy have made it necessary to redefine the role of surgery in the therapeutic algorithm in the management of lung cancer. Although video-assisted thoracic surgery lobectomy with hilar and mediastinal lymph node dissection was proposed over a decade ago to treat early lung cancer, this technique is currently not widely practiced, despite many documented advantages. This article examines the role of video-assisted thoracic surgery lobectomy in the treatment of early lung cancer and, in particular, variations in the approach and published results.

Entities:  

Mesh:

Year:  2007        PMID: 17626401     DOI: 10.1016/j.thorsurg.2007.03.009

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  4 in total

1.  Troubleshooting thoracoscopic anterior mediastinal surgery: lessons learned from thoracoscopic lobectomy.

Authors:  Sameer A Hirji; Scott S Balderson; Mark F Berry; Thomas A D'Amico
Journal:  Ann Cardiothorac Surg       Date:  2015-11

2.  Video-assisted thoracic surgery lobectomy: results in lung cancer.

Authors:  Jesús Loscertales; Florencio Quero Valen Zuela; Miguel Congregado; Rafael Jiménez Merchán; Gregorio Gallardo Varela; Ana Trivino Ramírez; Sergio B Moreno Merino; Fernando Cózar Bernal
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

3.  Flexible thoracoscopy may facilitate video-assisted thoracoscopic lobectomy.

Authors:  Peter B Licht; Lars Ladegaard
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

4.  Video-assisted thoracic surgery (VATS) compares favorably with thoracotomy for the treatment of lung cancer: a five-year outcome comparison.

Authors:  Xueying Yang; Shumin Wang; Jiaqi Qu
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.